Videos

Asian women who do not smoke in Northern California face rising lung cancer rates which are often diagnosed late due to current screening gaps.

Emmy-winning journalist and author Suleika Jaouad recently delivered the keynote address at the inaugural Blood Cancer Heroes celebration.

Emmy-winning journalist and author, Suleika Jaouad, delivered the keynote address at the inaugural Blood Cancer Heroes event.

In a recent interview with CURE, Dr. Kai Tsao discussed treatment advancements for patients with prostate cancer.

Dr. Robert Orlowski says a single-drug option in newly diagnosed myeloma may offer strong responses with fewer side effects and preserve future treatments.

Real-time text check-ins helped physicians identify issues sooner and support quality of life for patients with myeloma at ASH 2025.

Dr. Thomas Marron explains how therapeutic vaccines differ from preventative vaccines in lung cancer care.

Dr. Amany Keruakous discussed how bispecific antibodies for multiple myeloma work by simultaneously targeting cancer cells and T cells.

Dr. Ajay Gupta of the Roswell Park Comprehensive Cancer Center discussed basics of gastrointestinal stromal tumors.

Dr. Daniel Peters discussed targeted therapies and regimens that patients with acute myeloid leukemia, or AML, should be aware of.

Dr. Girindra Raval sat down for an interview with CURE to discuss what patients with EGFR-mutated lung cancer should know about their treatment options.

Nona Baker, who was first diagnosed with a blood cancer in 1991, shares her experience with polycythemia vera.

Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer.

Cindy and Katie share how finding a friend who understood the caregiving journey made the experience less isolating and helped them navigate loss and hope.

An expert explained what patients newly diagnosed with gastrointestinal stromal tumors need to know.

Cell therapies, which have made waves in the treatment of blood cancer, are showing potential for solid tumors.

Dr. Daniel J. Boffa discusses advancements in lung cancer care, including the role of minimally invasive surgical techniques and new systemic therapies.

CURE spoke with Dr. Marina Kremyanskaya about the treatment landscape for patients with polycythemia vera.

After more than 30 years since she was first diagnosed with a myeloproliferative neoplasm, Nona Baker is hopeful for the future thanks to current clinical trial landscape.

Dr. Pamela L. Kunz sat down for an interview with CURE to discuss resources and ongoing initiatives that may help patients with this disease.

Panelists discuss how healthcare providers and patients should understand that talquetamab's unique side effects are temporary and resolve over time even while continuing treatment, emphasizing the drug's excellent efficacy and the importance of removing stigma around its manageable toxicity profile.

Panelists discuss how effective caregivers should join support groups, maintain detailed records of symptoms and medications, attend all appointments, stay informed about myeloma research, and serve as active advocates who can communicate with healthcare teams when patients cannot.

Panelists discuss how patients beginning talquetamab should maintain a positive attitude, prepare thoroughly with educational materials, and understand that while initial side effects can be challenging, they are temporary and manageable with proper preparation and support.

Panelists discuss how patients can maintain nutrition during talquetamab treatment by focusing on texture and food presentation when taste is impaired, using high-calorie options, and remembering that taste changes and dry mouth are temporary side effects that improve over time.

Panelists discuss how specific talquetamab-related side effects like skin peeling, nail changes, and rashes can be effectively managed through targeted interventions including topical treatments, protective measures, and preventive strategies tailored to the drug's unique toxicity profile.

Panelists discuss how healthcare providers can develop comprehensive management protocols for talquetamab-related toxicities by consulting with specialists, gathering patient feedback, and creating detailed handouts that empower patients to proactively manage side effects before they begin treatment.

Panelists discuss how comprehensive patient education materials and manufacturer resources help patients prepare for and manage talquetamab side effects, with prior experience from CAR-T therapy providing valuable context for understanding potential complications like cytokine release syndrome.

Panelists discuss how healthcare providers must actively educate local oncologists, emergency departments, and community centers about bispecific antibody management as these therapies move from inpatient to outpatient settings, ensuring proper recognition and treatment of side effects like cytokine release syndrome.

Panelists discuss how successful talquetamab treatment requires coordinated care between inpatient and outpatient teams, comprehensive caregiver preparation including education materials and emergency contact information, and access to multidisciplinary healthcare providers as needed.